Researchers at Eindhoven University of Technology (TU/e) present a new method that should enable controlled drug delivery into the bloodstream using DNA computers. In the journal Nature Communications the team, led by biomedical engineer Maarten Merkx, describes how it has developed the first DNA computer capable of detecting several antibodies in the blood and performing subsequent calculations based on this input. This is an important step towards the development of smart, ‘intelligent’ drugs that may allow better control of the medication for rheumatism and Crohn’s disease, for example, with fewer side-effects and at lower cost.
An analogy for the method presented by the TU/e researchers is a security system that opens the door depending on the person standing in front of it. If the camera recognizes the person, the door unlocks, but if the person is unknown, the door remains locked. “Research into diagnostic tests tends to focus on the ‘recognition’, but what is special about this system is that it can think and that it can be connected to actuation such as drug delivery,” says professor of Biomedical Chemistry Maarten Merkx.
DNA computer
To be able to perform such an action, ‘intelligence’ is needed, a role that is performed in this system by a DNA computer. DNA is best known as a carrier of genetic information, but DNA molecules are also highly suitable for performing molecular calculations. The sequence within a DNA molecule determines with which other DNA molecules it can react, which allows a researcher to program desired reaction circuits.
Antibodies
To date biomedical applications of DNA computers have been limited because the input of DNA computers typically consists of other DNA and RNA molecules. To determine whether someone has a particular disease, it is essential to measure the concentration of specific antibodies – agents that our immune system produces when we are ill. Merkx and his colleagues are the first to have succeeded in linking the presence of antibodies to a DNA computer.
Drug delivery
Their method translates the presence of each antibody into a unique piece of DNA whereby the DNA computer can decide on the basis of the presence of one or more antibodies whether drug delivery, for example, is necessary. “The presence of a particular DNA molecule sets in motion a series of reactions whereby we can get the DNA computer to run various programs,” explains PhD student and primary author Wouter Engelen. “Our results show that we can use the DNA computer to control the activity of enzymes, but we think it should also be possible to control the activity of a therapeutic antibody.”
Medication
In treating chronic diseases like rheumatism or Crohn’s disease, such therapeutic antibodies are used as medication. One of the potential applications of this system is to measure the quantity of therapeutic antibodies in the blood and decide whether it is necessary to administer any extra medication. Merkx: “By directly linking the measurement of antibodies to the treatment of the disease, we may be able to prevent side-effects and reduce costs in the future.”
Learn more: DNA computer brings ‘intelligent drugs’ a step closer
[osd_subscribe categories=’smart-drug’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “INTELLIGENT DRUGS”‘]
Receive an email update when we add a new INTELLIGENT DRUGS article.
The Latest on: Intelligent drugs
[google_news title=”” keyword=”intelligent drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Intelligent drugs
- Phio Pharmaceuticals Secures New Investoron May 17, 2024 at 8:00 am
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is ...
- Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Eventon May 17, 2024 at 5:30 am
Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful exhibition of its Intelligent ...
- What Impact will AI have on Drug Safety and Regulatory Practices?on May 16, 2024 at 8:25 am
Until now, the business rationale has been undermined by the sheer amount of labor needed to validate and bring intelligent automation systems up to full functionality for life sciences R&D purposes, ...
- Lab Automation Market to be Worth $11.31 Billion by 2031 - Exclusive Report by Meticulous Research®on May 16, 2024 at 7:36 am
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the ...
- B&K Corp Seeks IPO To Keep Its Slow-Developing Drugs Aliveon May 16, 2024 at 7:04 am
B&K lost nearly 200 million yuan in the past two years, as its administrative expenses exceeded its R&D spending The drug maker’s president, who is also the founder’s son, has previous experience main ...
- Drug overdoses spiked in these states. But they have dropped elsewhere in the country.on May 15, 2024 at 8:07 am
Fewer Americans died of drug overdoses nationwide last year, marking the first annual drop since 2018, according to Centers for Disease Control and Prevention estimates released Wednesday.
- U.S. drug deaths declined slightly in 2023 but remained at crisis levelson May 15, 2024 at 8:01 am
Preliminary data released Wednesday from the Centers for Disease Control and Prevention found fatal drug overdoses in the U.S. fell by roughly 3% in 2023. That is a significant reversal from ...
- Schwab Intelligent Portfolios Review: Robo-Advisor for Large Balanceson May 14, 2024 at 4:57 am
For those who don't want to play an active role in their investments and also don't want to hire a financial advisor, Schwab offers the Schwab Intelligent Portfolios automated investing ...
- Schwab Intelligent Portfolios Review 2024on May 13, 2024 at 1:06 pm
See how we rate investing products to write unbiased product reviews. Schwab Intelligent Portfolios is Charles Schwab's algorithm-driven robo-advisor, offering customizable portfolios of low-cost ...
via Bing News